Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies

 

Show simple item record

dc.contributor.author Rayner, Brian
dc.contributor.author Jaeger, Bodo
dc.contributor.author Verboom, Cees-Nico
dc.contributor.author Pascoe, Michael
dc.date.accessioned 2016-09-19T06:47:08Z
dc.date.available 2016-09-19T06:47:08Z
dc.date.issued 2004
dc.identifier.citation Rayner, B., Jaeger, B., Verboom, C. N., & Pascoe, M. (2004). Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies. CARDIOVASCULAR JOURNAL OF SOUTH AFRICA, 15(1), 33.
dc.identifier.uri http://hdl.handle.net/11427/21790
dc.identifier.uri http://reference.sabinet.co.za/sa_epublication_article/cardio_v15_n1_a8
dc.description.abstract The importance of the renin-angiotensin-aldosterone system (RAAS) in the pathogenesis of hypertension and in renal disease, particularly in patients with diabetes, has become increasingly evident. Pharmacological blockade of the RAAS offers potential for the therapeutic management of these pathologies. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) receptor blockers have been shown to exhibit effectiveness in the treatment of hypertension. AII receptor blockers have a renal protective effect owing to their ability to reduce systemic blood and intraglomerular pressures. Eprosartan is a chemically distinct AII blocker, which displays a dual mode of action whereby it blocks both pre- and postsynaptic AT<sub>1</sub> receptors, potentially benefiting patients with hypertension and renal disease. In addition, evidence suggests that eprosartan is well tolerated by both healthy subjects and patients with varying degrees of renal impairment, such that the dose does not need to be - modified in patients with mild to moderate renal impairment. <br>Results from preliminary studies demonstrate that eprosartan doses well below those required for blood pressure control have a pronounced effect on the kidney and do not compromise renal autoregulatory mechanisms. Therefore, eprosartan may have a benefit in the prevention or delay of renal damage in hypertensive patients with renal impairment, although this remains to be determined in a clinical setting.
dc.language.iso eng
dc.source Cardiovascular Journal of South Africa
dc.source.uri http://www.cvja.co.za/information.php
dc.title Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies
dc.type Journal Article en_ZA
dc.date.updated 2016-01-07T08:07:35Z
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Department of Medicine en_ZA
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Rayner, B., Jaeger, B., Verboom, C., & Pascoe, M. (2004). Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies. <i>Cardiovascular Journal of South Africa</i>, http://hdl.handle.net/11427/21790 en_ZA
dc.identifier.chicagocitation Rayner, Brian, Bodo Jaeger, Cees-Nico Verboom, and Michael Pascoe "Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies." <i>Cardiovascular Journal of South Africa</i> (2004) http://hdl.handle.net/11427/21790 en_ZA
dc.identifier.vancouvercitation Rayner B, Jaeger B, Verboom C, Pascoe M. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies. Cardiovascular Journal of South Africa. 2004; http://hdl.handle.net/11427/21790. en_ZA
dc.identifier.ris TY - Journal Article AU - Rayner, Brian AU - Jaeger, Bodo AU - Verboom, Cees-Nico AU - Pascoe, Michael AB - The importance of the renin-angiotensin-aldosterone system (RAAS) in the pathogenesis of hypertension and in renal disease, particularly in patients with diabetes, has become increasingly evident. Pharmacological blockade of the RAAS offers potential for the therapeutic management of these pathologies. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) receptor blockers have been shown to exhibit effectiveness in the treatment of hypertension. AII receptor blockers have a renal protective effect owing to their ability to reduce systemic blood and intraglomerular pressures. Eprosartan is a chemically distinct AII blocker, which displays a dual mode of action whereby it blocks both pre- and postsynaptic AT<sub>1</sub> receptors, potentially benefiting patients with hypertension and renal disease. In addition, evidence suggests that eprosartan is well tolerated by both healthy subjects and patients with varying degrees of renal impairment, such that the dose does not need to be - modified in patients with mild to moderate renal impairment. <br>Results from preliminary studies demonstrate that eprosartan doses well below those required for blood pressure control have a pronounced effect on the kidney and do not compromise renal autoregulatory mechanisms. Therefore, eprosartan may have a benefit in the prevention or delay of renal damage in hypertensive patients with renal impairment, although this remains to be determined in a clinical setting. DA - 2004 DB - OpenUCT DP - University of Cape Town J1 - Cardiovascular Journal of South Africa LK - https://open.uct.ac.za PB - University of Cape Town PY - 2004 T1 - Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies TI - Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies UR - http://hdl.handle.net/11427/21790 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record